2/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2
08:13 am
arqt
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Low
Report
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
2/2
08:00 am
arqt
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
Low
Report
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
1/27
08:33 am
arqt
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]
1/26
11:34 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.
1/26
08:00 am
arqt
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
Low
Report
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
1/25
10:36 am
arqt
Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback [Yahoo! Finance]
1/25
06:31 am
arqt
Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Skin Insights Survey On Non Steroid Treatments [Yahoo! Finance]
Low
Report
Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Skin Insights Survey On Non Steroid Treatments [Yahoo! Finance]
1/22
05:00 pm
arqt
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference [Yahoo! Finance]
Low
Report
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference [Yahoo! Finance]
1/22
04:00 pm
arqt
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
Low
Report
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
1/21
10:32 am
arqt
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions [Yahoo! Finance]
Low
Report
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions [Yahoo! Finance]
1/21
08:00 am
arqt
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
Medium
Report
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
1/12
08:00 am
arqt
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
Medium
Report
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
1/4
01:06 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at
Wall S
Medium
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at
Wall S
12/24
06:32 pm
arqt
Is Suvretta's Stake Cut and FDA's Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? [Yahoo! Finance]
Low
Report
Is Suvretta's Stake Cut and FDA's Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? [Yahoo! Finance]
12/23
12:57 pm
arqt
Arcutis Stock Is Up 100% in a Year but Here's Why One Fund Still Sold 1 Million Shares [Yahoo! Finance]
Low
Report
Arcutis Stock Is Up 100% in a Year but Here's Why One Fund Still Sold 1 Million Shares [Yahoo! Finance]
12/14
03:02 pm
arqt
This Biotech Stock Could Cure Your Portfolio's Pain [Yahoo! Finance]
Low
Report
This Biotech Stock Could Cure Your Portfolio's Pain [Yahoo! Finance]
12/14
12:17 pm
arqt
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals [Yahoo! Finance]
Low
Report
Assessing Arcutis Biotherapeutics After 99% YTD Surge and Mixed Valuation Signals [Yahoo! Finance]
12/14
01:26 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at
Wall S
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was upgraded by analysts at
Wall S
12/8
04:00 pm
arqt
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Medium
Report
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
12/2
10:57 am
arqt
Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]
11/28
08:04 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.
11/27
01:47 pm
arqt
Tori Spelling And Daughter Stella Open Up About Struggles With Eczema [Forbes]
Low
Report
Tori Spelling And Daughter Stella Open Up About Struggles With Eczema [Forbes]
11/17
08:00 am
arqt
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
Medium
Report
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
11/13
08:38 am
arqt
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis [Yahoo! Finance]
Low
Report
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis [Yahoo! Finance]